HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders.
Market Cap | 2.429 Billion | Shares Outstanding | 264.316 Million | Avg 30-day Volume | 3.172 Million | ||
P/E Ratio | -8.77387 | Dividend Yield | EPS | -1.07 | |||
Price/Sales | 9.31 | Debt to Equity | 3.1 | EBITDA | -235.008 Million | ||
Price to Book Value | 8.48 | Forward PE | -10.74 | Enterprise Value | 2.335 Billion | ||
Total Cash | 483.269 Million | Current Debt | 129.676 Million | Gross Profit | 229.842 Million | ||
BETA | 1.11293 | 52-week High/Low | 25.39 / 8.83 | Next Earnings Date | 2021-05-06 | Price to Cash FLow (P/CF) | -9999999.0 |
Data provided by IEX Cloud |
Q4 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 6 | 6 | 0.0% | 6 (0.36%) | 6 (0.37%) | 0.0% |
Funds Holding: | 268 | 248 | 8.06% | 90 (5.41%) | 88 (5.48%) | 2.27% |
13F shares: | 278.931 Million | 274.227 Million | 1.72% | 138.55 Million | 134.959 Million | 2.66% |
% Ownership | 53.1684 | 51.7901 | 2.66% | |||
New Positions: | 49 | 44 | 11.36% | 13 | 18 | -27.78% |
Increased Positions | 88 | 76 | 15.79% | 25 | 31 | -19.35% |
Closed Positions | 27 | 19 | 42.11% | 11 | 7 | 57.14% |
Reduced Positions | 96 | 93 | 3.23% | 40 | 34 | 17.65% |
Total Calls | 3.603 Million | 2.617 Million | 37.64% | 1.425 Million | 977 Thousand | 45.84% |
Total Puts | 3.715 Million | 999.412 Thousand | 271.74% | 2.225 Million | 478 Thousand | 365.42% |
PUT/CALL Ratio | 1.03 | 0.38 | 171.05% | 1.56 | 0.49 | 218.37% |
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
3 Thousand total shares from 2 transactions
95.4 Thousand total shares from 8 transactions
81.7 Thousand total shares from 5 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
CROWLEY JOHN F CHAIRMAN & CEO |
|
964,808 | 2021-04-06 | 23 |
CAMPBELL BRADLEY L CHIEF OPERATING OFFICER |
|
412,022 | 2021-04-06 | 17 |
QUIMI DAPHNE CHIEF FINANCIAL OFFICER |
|
290,629 | 2021-04-06 | 9 |
DO HUNG CHIEF SCIENCE OFFICER |
|
448,617 | 2021-04-06 | 6 |
ROSENBERG ELLEN CHIEF LEGAL OFFICER |
|
256,206 | 2021-04-06 | 5 |
CLARK DAVID MICHAEL CHIEF PEOPLE OFFICER |
|
174,389 | 2021-04-06 | 3 |
|
44,467 | 2021-04-01 | 12 | |
PROUT SAMANTHA PRINCIPAL ACCOUNTING OFFICER |
|
26,255 | 2021-01-02 | 6 |
|
8,837 | 2020-12-01 | 2 | |
BARTH JAY CHIEF MEDICAL OFFICER |
|
163,224 | 2020-09-30 | 7 |
|
27,919 | 2020-06-04 | 1 | |
|
21,000 | 2020-06-04 | 2 | |
|
33,933 | 2020-06-04 | 1 | |
|
131,000 | 2020-06-04 | 1 | |
|
21,000 | 2020-06-04 | 1 | |
|
21,000 | 2020-06-04 | 1 | |
|
21,705 | 2020-06-04 | 1 | |
|
20,724,424 | 2019-02-12 | 0 | |
BAIRD WILLIAM D III CHIEF FINANCIAL OFFICER |
|
117,622 | 2018-10-15 | 0 |
ANDREWS KURT J. SVP, HUMAN RESOURCES |
|
35,469 | 2018-07-02 | 0 |
|
8,895 | 2018-06-07 | 0 | |
|
0 | 2016-06-09 | 0 | |
|
12,890,146 | 2016-06-03 | 0 | |
PEIST KENNETH VP, LEGAL & IP |
|
18,874 | 2016-01-04 | 0 |
VALENZANO KEN SVP, PHARMACOLOGY & BIOLOGY |
|
27,687 | 2015-07-13 | 0 |
DOSHI DIPAL SVP STRATEGY & BUS DEV |
|
1,706 | 2015-07-07 | 0 |
GERSHKOWITZ JAYNE SVP, CHIEF PATIENT ADVOCATE |
|
5,693 | 2015-07-01 | 0 |
CASTELLI JEFF SVP, PROGRAM MANAGEMENT |
|
25,000 | 2015-06-22 | 0 |
DILONE ENRIQUE SVP, TECHNICAL OPERATIONS |
|
30,688 | 2015-06-19 | 0 |
YU JULIE VP CLINICAL OPS & DATA MGMT |
|
0 | 2015-06-15 | 0 |
KIRK JOHN VP, REGULATORY AFFAIRS |
|
0 | 2015-06-01 | 0 |
BALDRY MARK VP GLOBAL MARKETING |
|
25,000 | 2015-06-01 | 0 |
DAVID ALLSOP SVP INTERNATIONAL |
|
0 | 2015-04-27 | 0 |
|
No longer subject to file | 2014-10-27 | 0 | |
|
0 | 2014-06-12 | 0 | |
|
0 | 2014-06-12 | 0 | |
LOCKHART DAVID J CHIEF SCIENTIFIC OFFICER |
|
0 | 2013-06-18 | 0 |
WINTERBOTTOM JOAN SVP, HUMAN RESOURCES |
|
0 | 2013-06-18 | 0 |
MACALUSO PETER M VP & CORPORATE COUNSEL |
|
0 | 2013-06-18 | 0 |
WINKLER ROBERT E VP, CLIN RESEARCH & OPERATIONS |
|
0 | 2012-06-04 | 0 |
BOUDES POL F CHIEF MEDICAL OFFICER |
|
0 | 2012-06-04 | 0 |
GILMORE GEOFFREY SVP & GENERAL COUNSEL |
|
0 | 2012-03-12 | 0 |
|
5,650,340 | 2012-03-07 | 0 | |
|
5,650,340 | 2012-03-07 | 0 | |
|
5,650,340 | 2012-03-07 | 0 | |
|
5,650,340 | 2012-03-07 | 0 | |
|
4,584,311 | 2012-03-07 | 0 | |
SCHAEFFER ORLOV S NICOLE SVP, HR & LEADERSHIP DEVT |
|
0 | 2012-02-15 | 0 |
|
0 | 2011-05-24 | 0 | |
PATTERSON MATTHEW R ACTING CEO & PRESIDENT |
|
106,547 | 2011-04-18 | 0 |
|
0 | 2010-06-15 | 0 | |
JOHN MCADAM M VP, FINANCE & ACCOUNTING |
|
0 | 2010-06-15 | 0 |
DENTZER JAMES E CHIEF FINANCIAL OFFICER |
|
32,075 | 2009-10-01 | 0 |
PALLING DAVID SR VP, TECHNICAL OPERATIONS |
|
34,040 | 2009-06-26 | 0 |
|
1,714,090 | 2009-02-11 | 0 | |
LICHOLAI GREGORY P VP, MEDICAL AFFAIRS |
|
0 | 2009-02-03 | 0 |
SHENKER ANDREW VP, CLINICAL RESEARCH |
|
0 | 2009-02-03 | 0 |
|
2,058,555 | 2008-08-14 | 0 | |
FRAZIER HEALTHCARE IV LP FRAZIER AFFILIATES IV LP |
|
915,924 | 2008-03-06 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-04-08 20:06:06 -0400 | 2021-04-06 | A | 16,883 | a | 174,389 | direct | 1.0881 | 8.161 | 12.4048 | 5 | 0.0 | 1 | ||||
2021-04-08 20:00:18 -0400 | 2021-04-06 | A | 20,501 | a | 241,206 | direct | 1.0881 | 8.161 | 12.4048 | 5 | 0.0 | 1 | ||||
CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER |
2021-04-08 20:03:06 -0400 | 2021-04-06 | A | 33,165 | a | 412,022 | direct | 1.0881 | 8.161 | 12.4048 | 5 | 0.0 | 1 | |||
2021-04-08 20:01:37 -0400 | 2021-04-06 | A | 19,295 | a | 290,629 | direct | 1.0881 | 8.161 | 12.4048 | 5 | 0.0 | 1 | ||||
2021-04-08 20:05:06 -0400 | 2021-04-06 | A | 20,501 | a | 448,617 | direct | 1.0881 | 8.161 | 12.4048 | 5 | 0.0 | 1 | ||||
2021-04-08 20:04:03 -0400 | 2021-04-06 | A | 78,389 | a | 899,913 | direct | 1.0881 | 8.161 | 12.4048 | 5 | 0.0 | 1 | ||||
CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER |
2021-04-05 18:19:13 -0400 | 2021-04-01 | S | 10,514 | $10.03 | d | 378,857 | direct | yes | -1.9874 | -2.6151 | 0.0 | 1 | -3.8703 | 4 | |
2021-04-05 18:15:17 -0400 | 2021-04-01 | P | 1,500 | $10.00 | a | 44,467 | direct | yes | -1.9874 | -2.6151 | 0.0 | 1 | -3.8703 | 4 | ||
CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER |
2021-04-05 18:19:13 -0400 | 2021-04-01 | M | 10,514 | $6.45 | a | 389,371 | direct | -1.9874 | -2.6151 | 0.0 | 1 | -3.8703 | 4 | ||
CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER |
2021-04-05 18:19:13 -0400 | 2021-04-01 | M | 10,514 | d | 17,137 | direct | |||||||||
2021-04-05 18:17:23 -0400 | 2021-04-01 | S | 7,500 | $10.00 | d | 821,524 | direct | yes | -1.9874 | -2.6151 | 0.0 | 1 | -3.8703 | 4 | ||
2021-03-30 17:26:33 -0400 | 2021-03-26 | F | 435 | $9.59 | d | 64,674 | direct | 1.8219 | -6.1741 | 1.8219 | 2 | -6.1741 | 6 | |||
2021-03-24 17:11:56 -0400 | 2021-03-22 | S | 7,682 | $10.29 | d | 829,024 | direct | yes | 0.9474 | 5.8947 | 5.8947 | 6 | -3.1579 | 3 | ||
2021-03-17 19:11:17 -0400 | 2021-03-15 | M | 22,000 | d | 42,557 | direct | ||||||||||
2021-03-17 19:11:17 -0400 | 2021-03-15 | S | 22,000 | $10.77 | d | 836,706 | direct | yes | 0.8858 | -6.4961 | 2.7559 | 3 | -7.6772 | 5 | ||
2021-03-17 19:11:17 -0400 | 2021-03-15 | M | 22,000 | $6.45 | a | 858,706 | direct | 0.8858 | -6.4961 | 2.7559 | 3 | -7.6772 | 5 | |||
2021-03-09 17:38:33 -0500 | 2021-03-05 | M | 16,628 | d | 0 | direct | ||||||||||
2021-03-09 17:38:33 -0500 | 2021-03-05 | F | 4,664 | $10.48 | d | 271,334 | direct | 3.8499 | 1.4437 | 3.9461 | 4 | 0.0 | 1 | |||
2021-03-09 17:38:33 -0500 | 2021-03-05 | M | 16,628 | $2.94 | a | 275,998 | direct | 3.8499 | 1.4437 | 3.9461 | 4 | 0.0 | 1 | |||
CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER |
2021-03-03 19:03:19 -0500 | 2021-03-01 | M | 10,514 | d | 27,651 | direct | |||||||||
2021-03-03 19:04:09 -0500 | 2021-03-01 | S | 7,500 | $11.85 | d | 836,706 | direct | yes | 1.256 | 4.2512 | -3.9614 | 4.3478 | 8 | -11.2077 | 26 | |
CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER |
2021-03-03 19:03:19 -0500 | 2021-03-01 | S | 10,514 | $11.84 | d | 378,857 | direct | yes | 1.256 | 4.2512 | -3.9614 | 4.3478 | 8 | -11.2077 | 26 |
2021-03-03 18:58:46 -0500 | 2021-03-01 | P | 1,500 | $12.40 | a | 42,967 | direct | yes | 1.256 | 4.2512 | -3.9614 | 4.3478 | 8 | -11.2077 | 26 | |
CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER |
2021-03-03 19:03:19 -0500 | 2021-03-01 | M | 10,514 | $6.45 | a | 389,371 | direct | 1.256 | 4.2512 | -3.9614 | 4.3478 | 8 | -11.2077 | 26 | |
2021-02-24 17:07:50 -0500 | 2021-02-22 | S | 7,682 | $11.98 | d | 844,206 | direct | yes | 3.0201 | -13.1711 | -22.9027 | 3.0201 | 2 | -22.9027 | 31 | |
2021-02-18 18:48:48 -0500 | 2021-02-16 | M | 22,000 | $6.45 | a | 873,888 | direct | -2.9869 | 0.491 | -18.6579 | 0.491 | 6 | -24.7136 | 27 | ||
2021-02-18 18:48:48 -0500 | 2021-02-16 | M | 22,000 | d | 64,557 | direct | ||||||||||
2021-02-18 18:48:48 -0500 | 2021-02-16 | S | 22,000 | $12.26 | d | 851,888 | direct | yes | -2.9869 | 0.491 | -18.6579 | 0.491 | 6 | -24.7136 | 27 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 22:15:03 UTC | -0.2191 | 0.2791 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 21:45:03 UTC | -0.2191 | 0.2791 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 21:15:02 UTC | -0.2191 | 0.2791 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 20:45:03 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 20:15:04 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 19:45:03 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 19:15:03 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 18:45:03 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 18:15:03 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 17:45:03 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 17:15:03 UTC | -0.2624 | 0.3224 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 16:45:02 UTC | -0.19 | 0.25 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 16:15:03 UTC | -0.19 | 0.25 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 15:45:03 UTC | -0.19 | 0.25 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 15:15:03 UTC | -0.19 | 0.25 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 14:45:03 UTC | -0.2091 | 0.2691 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 14:15:02 UTC | -0.2091 | 0.2691 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 13:45:03 UTC | -0.2091 | 0.2691 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 13:15:03 UTC | -0.2091 | 0.2691 | 2100000 |
AMICUS THERAPEUTICS INC FOLD | 2021-04-16 12:45:02 UTC | -0.2091 | 0.2691 | 2100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Hedged Plus Fund | FOLD | -2082.0 shares, $-48073.38 | 2020-12-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | FOLD | -130.0 shares, $-1201.2 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Master Neutral Fund | FOLD | -144.0 shares, $-2033.28 | 2020-09-30 | N-PORT |
VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND | FOLD | -42442.0 shares, $-979985.78 | 2020-12-31 | N-PORT |